USPTO serial 79338173
ENTEROBIOTIX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 15, 2026
- Examiner
- RIRIE, VERNA BETH
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ENTEROBIOTIX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
P. Jay Hines
P. Jay Hines Muncy, Geissler, Olds & Lowe, P.C.125 S. Royal St.Alexandria, VA 22314United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals, reagents and chemical substances for medical research laboratory purposes; chemical substances for use in the manufacture of medicinal and pharmaceutical products; diagnostic preparations and reagents for scientific or research use; enzymes for scientific purposes; raw proteins for scientific and medical research; proteins for use in industry and in science; diagnostic test kits for scientific or research use, comprised of buffer solutions, assays and reagents | ACTIVE | — |
| 005 | Pharmaceutical, medical and veterinary preparations for the treatment of gastrointestinal issues; pharmaceutical, medical and veterinary preparations in the field of microbiome modulating therapeutic vaccines; Pharmaceutical, medical and veterinary preparations in the field of microbiome modulating therapeutic medicines, namely, pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of abnormalities in human genetics, the human immune system, the human gut microbiome and other gastrointestinal disorders and diseases; pharmaceutical preparations and pepsins for the treatment of gastrointestinal disorders and diseases; biological preparations for medicinal use, namely, pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; biological compounds for use in targeted pharmaceutical therapies, namely protein arrays for medical diagnostic purposes in the field of abnormalities in the human immune system, the human gut microbiome and other gastrointestinal disorders and diseases; proteins with diagnostic and therapeutic uses, namely, protein arrays for medical diagnostic purposes; chemical and enzyme preparations for medical or veterinary sanitary purposes; reagents and diagnostic preparations for use in testing for medical and veterinary purposes; drug delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical preparations; intestinal microbiome pharmaceutical preparations; clinical medical reagents; diagnostic reagents and assay components for clinical, medical and medical laboratory use; enzymes for medical purposes; yeast for intracellular production of recombinant proteins being biochemical preparations for medical purposes; yeast for pharmaceutical purposes; dietary supplements; food supplements; topical gels for medical and therapeutic use in the treatment of abnormalities in the human immune system, the human gut microbiome and other gastrointestinal disorders and diseases; intestinal microbiome medicinal preparations; pharmaceutical and therapeutic preparations for use in the treatment related abnormalities in the fields of microbiology, genetics, the human immune system, the human gut microbiome or gastrointestinal health; diagnostic preparations for clinical medical use in the fields of microbiology, genetics, the human immune system, the human gut microbiome or gastrointestinal health; medical bacterial preparations for use in connection with intestinal microbiota transfer; chemical reagent preparations for use in medicine; diagnostic biomarker reagents for in vitro or in vivo testing for medical use | ACTIVE | — |
| 009 | Downloadable computer software for mobile applications for use in operating biometric medical devices; downloadable cloud computing software for use in operating biometric medical devices; downloadable computer software to allow biometric devices and computers to be interoperable and compatible; downloadable computer software for managing databases and electronic directories; downloadable artificial intelligence software for healthcare management use; downloadable computer software for operating health monitoring devices; downloadable computer software for use interpreting research data in the fields of physiology, biology, genetics, genomics, metagenomics, microbiome, metabolomics, proteomics, glycomics, biochemistry, probiotics and/or prebiotics; downloadable computer software for use storing research data in the fields of biotechnology, microorganisms, cells, pharmaceuticals, medicine, molecular sciences and/or bacteria; downloadable database management computer software for scientific analysis of genetic sequences; Downloadable interactive computer software for treating abnormalities in the human immune system, the human gut microbiome or other gastrointestinal diseases; downloadable media streaming software; downloadable machine learning software for healthcare; downloadable machine learning software for scientific research analysis; downloadable computer software for remote monitoring and analysis of gut bacteria; downloadable computer application software for streaming audio-visual media content via the internet; downloadable computer programs for the analysis of the human gut microbiome for use in medical research studies; wearable activity tracker devices for taking biological measurements; instruments for analysing physical data being downloadable software for analysing data from the human gut microbiome; downloadable publications in electronic form, namely, journals, papers, articles and magazines featuring medical research; scientific apparatus and instruments for measuring DNA, RNA, proteins and bacteria; apparatus and instruments for the recording, transmission or reproduction of data, sound or images; devices for analysing protein sequence used as laboratory apparatus; computers and computer hardware; blank smart cards; smart card readers; electronically encoded identity bracelets; replacement parts for all the aforesaid goods | ACTIVE | — |
| 010 | Medical devices for use in diagnosing and treating gastrointestinal disorders and diseases; medical apparatus and instruments for collecting and storing human faeces; medical apparatus and instruments for administering gastrointestinal medicine; Medical apparatus and instruments for analyzing and identifying bacteria; medical apparatus for introducing pharmaceutical preparations into the human body; medical introducer instruments for use in connection with intestinal microbiota transfer ; blood testing instruments and instruments for testing faeces for medical diagnostic purposes in relation to genetics, the human immune system and the human gut microbiome; medical diagnostic blood testing apparatus in the field of microbiology; diagnostic and medical DNA testing apparatus in the field of microbiome modulating therapeutics; medical diagnostic DNA testing apparatus in the fields of microbiology, genetics, the human immune system, the human gut microbiome or gastrointestinal health; gloves for medical examinations; bags adapted for medical use, namely bags for collecting and storing samples of human or animal waste;; and replacement parts for the aforesaid goods | ACTIVE | — |
| 042 | Research and development services in the fields of medicine and health; research and development in the pharmaceutical and biotechnology fields; biological, scientific, clinical and medical research and development; drug discovery services; pharmaceutical drug development services; research and development of vaccines and medicines; research and development of compounds for use in targeted pharmaceutical therapies; medical and pharmacological research services; research relating to molecular sciences and biotechnology; research and development in the field of microorganisms and cells; research and development in the field of therapeutics; scientific and medical research services in the field of microbiome modulating therapeutics; research and development of pharmaceutical preparations for the treatment of gastrointestinal disorders and diseases; research and development of biological drug delivery platforms; biochemical research and analysis; bacteriological research and analysis; scientific analysis of bodily fluids in the field of intestinal microbiology for medical research; analysis of human excreta for medical research; microbiological bacteriological testing and biological analysis for medical research; medical research comprising development, analysis and evaluation services in connection with biotechnology, microorganisms, cells, pharmaceuticals, medicine, molecular sciences, bacteria, physiology, biology, genetics, genomics, microbiome, metabolomics, proteomics, glycomics, biochemistry, probiotics, prebiotics and nutraceutical supplements; scientific research and development services in connection with health care, wellness, physical well-being, mental well-being, exercise, weight planning, weight management, diet, nutrition and/or sleep; scientific research, development, analysis and evaluation services in connection with microbiology, genetics, the human immune system and the human gut microbiome; research and development in connection with gastrointestinal health; DNA screening for scientific research purposes; testing of pharmaceuticals; product quality testing for the purpose of testing, authentication and quality control; biotechnology research and chemical testing; custom design and development of biochemical reagents; scientific laboratory services; clinical research, namely, conducting clinical trials for others; conducting early evaluations in the field of new pharmaceuticals; pharmaceutical research and development for use in clinical trials; providing information about the results of clinical trials for pharmaceutical products; technical measuring and testing of products of others; structural and functional analysis of genomes; services for assessing the efficiency of medical and veterinary drugs; veterinary research and development services; new product design and development; design services relating to the biotechnology industry; analysis of product development; pharmaceutical product evaluation; scientific research and the preparation of scientific reports in the field of biotechnology and/or gut health associated therewith; scientific research and analysis; consulting services for others in the field of design, planning and implementation scientific research project management in the field of scientific research; assessment of risks related to scientific research; industrial analysis and research in the field of biotechnology; analysis of product design, namely, product design and development in the field of medical devices and new pharmaceuticals; quality assessment; software design, development, programming and implementation; software engineering; development and design of software in the field of mobile applications; computer programming; development of computer platforms; design, development and testing of computing methods, algorithms and software; software as a service [SAAS] featuring software for analyzing data from medical research; platform as a service [PaaS] featuring computer software platforms for analyzing and storing data from medical research; platform as a service featuring a computer software platform that enables access to technical studies and scientific and medical information; application service provider (ASP), namely, hosting computer software applications of others; computer software maintenance; research and development of computer software algorithms; information technology consulting services relating to the installation, maintenance and repair of computer software for the pharmaceutical and healthcare industries; writing of computer programs for biotechnological applications; development of virtual reality software; design and development of software for use in the fields of biotechnology, microorganisms, cells, pharmaceuticals, medicine, molecular sciences and/or bacteria; database design; maintenance of database software; design and development of computer hardware; online electronic data storage; cross-platform conversion of digital content into other forms of digital content; scientific research in the nature of technical data analysis of results of scientific experiments; data encryption services; updating of software; rental of computer software for use in analyzing results of scientific experiments; data coding services being computer programming; process monitoring for product quality assurance; hosting websites on the internet in the field of healthcare and wellness; DNA sequencing and sequencing of microbiomes in humans for medical research purposes; consultancy, information and advisory services relating to all of the aforesaid services | ACTIVE | — |
| 044 | Medical and healthcare services; medical examinations; medical analysis services; health assessment surveys; health risk assessment surveys; medical health assessment services; medical analysis services relating to the treatment of persons; medical care services relating to patient treatment; analysis of human tissues for medical treatment; genetic testing for medical purposes; DNA screening for medical purposes; medical and health care services relating to utilizing DNA, genetics and genetic testing; medical services relating to DNA sequencing and sequencing of microbiomes in humans; diagnostic testing and analysis services for medical purposes; analysis of human serum for medical treatment; analysis of human excreta for medical treatment; human serum donation services; donation of bodily fluids and human waste; donation of human excreta; behavioural analysis for medical purposes; psychological assessment services; providing online medical record services; providing patient medical information in the form preparation of reports relating to medical matters; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; providing health information via a website; medical services connected with intestinal microbiota transfer; consultancy, information and advisory services relating to all of the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Enterobiotix Limited
- Other trademarks owned by Enterobiotix Limited
- Other trademarks owned by Enterobiotix Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ENTEROBIOTIX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 15, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 15, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 28, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 28, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 23, 2026 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 22, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 8, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 8, 2026 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 26, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 25, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 25, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 25, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 25, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 7, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 29, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 15, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 19, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 19, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 19, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| May 19, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 2, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 2, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 2, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 9, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 20, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 20, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jun 8, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 8, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 8, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 21, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 21, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 21, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Feb 21, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 21, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 21, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 29, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 24, 2022 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Dec 8, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 8, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 27, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 26, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 12, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 19, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 15, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 14, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |